Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium.

Medvec AR, Ecker C, Kong H, Winters EA, Glover J, Varela-Rohena A, Riley JL.

Mol Ther Methods Clin Dev. 2017 Nov 7;8:65-74. doi: 10.1016/j.omtm.2017.11.001. eCollection 2018 Mar 16.

2.

Differential Reliance on Lipid Metabolism as a Salvage Pathway Underlies Functional Differences of T Cell Subsets in Poor Nutrient Environments.

Ecker C, Guo L, Voicu S, Gil-de-Gómez L, Medvec A, Cortina L, Pajda J, Andolina M, Torres-Castillo M, Donato JL, Mansour S, Zynda ER, Lin PY, Varela-Rohena A, Blair IA, Riley JL.

Cell Rep. 2018 Apr 17;23(3):741-755. doi: 10.1016/j.celrep.2018.03.084.

3.

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.

Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, Bossi G, Vuidepot A, Powlesland AS, Legg A, Adams KJ, Bennett AD, Pumphrey NJ, Williams DD, Binder-Scholl G, Kulikovskaya I, Levine BL, Riley JL, Varela-Rohena A, Stadtmauer EA, Rapoport AP, Linette GP, June CH, Hassan NJ, Kalos M, Jakobsen BK.

Sci Transl Med. 2013 Aug 7;5(197):197ra103. doi: 10.1126/scitranslmed.3006034.

4.

The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells.

Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela-Rohena A, Golovina TN, Carroll RG, Riley JL, June CH.

Sci Transl Med. 2010 Oct 27;2(55):55ra78. doi: 10.1126/scitranslmed.3000448.

5.

Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein.

Francica JR, Varela-Rohena A, Medvec A, Plesa G, Riley JL, Bates P.

PLoS Pathog. 2010 Sep 9;6(9):e1001098. doi: 10.1371/journal.ppat.1001098.

6.

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, Carroll RG, Riley JL, Pastan I, June CH.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3360-5. doi: 10.1073/pnas.0813101106. Epub 2009 Feb 11.

7.

Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor.

Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, Carroll RG, Milicic A, Mahon T, Sutton DH, Laugel B, Moysey R, Cameron BJ, Vuidepot A, Purbhoo MA, Cole DK, Phillips RE, June CH, Jakobsen BK, Sewell AK, Riley JL.

Nat Med. 2008 Dec;14(12):1390-5. doi: 10.1038/nm.1779. Epub 2008 Nov 9.

8.

Genetic engineering of T cells for adoptive immunotherapy.

Varela-Rohena A, Carpenito C, Perez EE, Richardson M, Parry RV, Milone M, Scholler J, Hao X, Mexas A, Carroll RG, June CH, Riley JL.

Immunol Res. 2008;42(1-3):166-81. doi: 10.1007/s12026-008-8057-6. Review.

9.

Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.

Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela-Rohena A, Milone MC, Carroll RG, Riley JL, June CH.

Mol Ther. 2007 May;15(5):981-8. Epub 2007 Mar 20.

10.

HIV-1 tropism for the central nervous system: Brain-derived envelope glycoproteins with lower CD4 dependence and reduced sensitivity to a fusion inhibitor.

Martín-García J, Cao W, Varela-Rohena A, Plassmeyer ML, González-Scarano F.

Virology. 2006 Mar 1;346(1):169-79. Epub 2005 Nov 23.

Supplemental Content

Loading ...
Support Center